<PAGE>
SECURTIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 26, 1996
------------------------------
CardioDynamics International Corporation
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 0-11868 95-3533362
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
6155 Cornerstone Court East, Suite 125, San Diego, California 92121
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (619) 535-0202
------------------------
n/a
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
On November 26, 1996 CardioDynamics International Corporation received 510(k)
marketing clearance from the FDA for its key product, the BioZ-TM- non-invasive
hemodynamic monitoring system. The company will begin marketing the product
immediately.
The BioZ System, which can be used as an alternative to the invasive right heart
catheter, is a digital signal processor-based noninvasive hemodynamic monitoring
system utilizing the company's patented thoracic electrical bioimpedance (TEB)
technology.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CARDIODYNAMICS INTERNATIONAL
CORPORATION
By: /s/ Richard E. Otto
-------------------------
Richard E. Otto, Chief Executive Officer
Date: December 5, 1996
